InsiderPulse| Trade Date | Filed | Owner | Role | Type | Shares | Price | Value | Owned After | ||
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | 2026-05-28 | GC Corp. | 10% Owner | Purchase | 1.43M | $11.52 | $16.50M | 4.39M | View ↗ | |
| 2026-05-19 | 2026-05-19 | Raymon Heather | SVP, Research and Development | Sale | 3,095 | $9.01 | $28K | 148.2K | View ↗ | |
| 2026-05-19 | 2026-05-19 | Horan Christopher | Chief Tech Operations Officer | Sale | 7,002 | $9.01 | $63K | 293.4K | View ↗ | |
| 2026-05-19 | 2026-05-19 | Bush Jennifer | COO, CLO, Compliance Officer | Sale | 8,790 | $9.01 | $79K | 337.9K | View ↗ | |
| 2026-05-19 | 2026-05-19 | Banerjee Subhashis | Chief Medical Officer | Sale | 7,037 | $9.01 | $63K | 145.0K | View ↗ |
No annual data found.
Artiva Biotherapeutics to Participate in the 2026 Jefferies Global Healthcare Conference
Artiva Biotherapeutics Announces Multiple AlloNK® Data Presentations at EULAR 2026 Congress, Including Late-Breaking Oral Presentation Highlighting Clinical Efficacy Comparable to Autologous CAR T-Cell Therapy in Rheumatologic Diseases
Artiva Biotherapeutics Appoints Veteran Biotech Executive and Drug Developer Diego Miralles, M.D., as President and Head of Research and Development
Artiva Biotherapeutics: 'Buy' On AlloNK POC And FDA Phase 3 Alignment For Refractory RA